Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PDE8B | O95263 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM4B | O94953 | 1/20 | 0.33 |
| ▸ | KDM5C | P41229 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | ALPI | P09923 | 1/20 | 0.32 |
| ▸ | ALPG | P10696 | 1/20 | 0.32 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12026627 | 0.84 | ACHE (0.44) | ACHEL3MBTL1PDE8BMAPTKMT2A | |
| SCHEMBL13181031 | 0.82 | ACHE (0.40) | ACHEL3MBTL1PDE8BMAPTKMT2A | |
| SCHEMBL7459073 | 0.81 | ACHE (0.39) | ACHEL3MBTL1PDE8BMAPTKMT2A | |
| SCHEMBL13126452 | 0.79 | ACHE (0.38) | ACHEL3MBTL1PDE8BMAPTKDM4E | |
| SCHEMBL1161159 | 0.78 | ACHE (0.42) | ACHEL3MBTL1PDE8BMAPTKMT2A | |
| SCHEMBL23638714 | 0.77 | TDP1 (0.39) | ACHEL3MBTL1MAPTKDM4EKMT2A | |
| SCHEMBL21743170 | 0.76 | GABRA1 (0.50) | ACHEL3MBTL1PDE8BMAPTKMT2A | |
| SCHEMBL21303995 | 0.76 | ACHE (0.41) | ACHEL3MBTL1PDE8BMAPTKMT2A | |
| SCHEMBL1106841 | 0.76 | ACHE (0.41) | ACHEL3MBTL1PDE8BMAPTKMT2A | |
| SCHEMBL5212545 | 0.76 | ACHE (0.41) | ACHEL3MBTL1PDE8BMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024018403-A1 | SUBSTITUTED IMIDAZOAMIDE COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-01-25 | — | — | WO | disclosed |
| EP-1663971-B1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | LILLY CO ELI (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-1663971-B1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | LILLY CO ELI (US) | 2011-12-21 | — | — | EP | disclosed |
| CN-1849307-B | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists | LILLY CO ELI | 2011-08-03 | — | — | CN | disclosed |
| US-20110034511-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034511-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034511-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2011-02-10 | — | — | US | disclosed |
| US-7803813-B2 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803813-B2 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803813-B2 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| CN-1849307-A | As 5-HT1FSubstituted 2-carbonylamino-6-agonistsPiperidinylaminopyridines and substituted 1-carbonylamino-3-piperidinylaminophenyls | LILLY CO ELI (US) | 2006-10-18 | — | — | CN | disclosed |
| EP-1663971-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | Eli Lilly and Company (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005035499-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
| EP-0768301-B1 | N-(2-substituted-3-(2-aminoethyl)-1H-indol-5-yl)-amides as new 5-HT1F agonists | LILLY CO ELI (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6126932-A | INSOLUBLE POLYMER BEARING PENDANT SIDE CHAINS, SAID SIDE CHAINS EACH TERMINATING WITH THE 1-(3-(1-PYRROLIDINYL)-PROPYL)-3-ETHYLCARBODIIMIDE MOIETY. | ELI LILLY AND COMPANY (US) | 2000-10-03 | — | — | US | disclosed |
| EP-0994109-A2 | 1-(3-(1-Pyrrolidinyl)propyl)-3-ethylcarbodiimide and a solid phase coupling agent | ELI LILLY AND COMPANY (US) | 2000-04-19 | — | — | EP | disclosed |
| US-5998630-A | A 1-(3-(1-PYRROLIDINYL)PROPY)-3-ETHYLCARBODIIMIDE | ELI LILLY AND COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| US-5942536-A | USEFUL FOR TREATING MIGRAINE | ELI LILLY AND COMPANY (US) | 1999-08-24 | — | — | US | disclosed |
| WO-1997013512-A1 | N-[2-SUBSTITUTED-3-(2-AMINOETHYL)-1H-INDOL-5-YL]-AMIDES: NEW 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1997-04-17 | — | — | WO | disclosed |
| EP-0768301-A1 | N-(2-substituted-3-(2-aminoethyl)-1H-indol-5-yl)-amides as new 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 1997-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034511-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | HTR1F, HTR1A, HTR3B | ACHE 1785/4885L3MBTL1 2144/4885PDE8B 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.